top of page
Browse by category
Search


FLOW trial: Semaglutide 1.0mg demonstrates 24% reduction in the risk of kidney disease-related events in T2DM and chronic kidney disease patients
Headline results from the kidney outcomes trial FLOW (Effect of Semaglutide Versus Placebo on the Progression of Renal Impairment in...


Spatz3 Adjustable Gastric Balloon launched in the US
Spatz Medical has announced the launch of the Spatz3 Adjustable Gastric Balloon in the US. The Spatz3 Adjustable Gastric Balloon,...


The number of people living with obesity passes one billion
The total number of children, adolescents and adults worldwide living with obesity has surpassed one billion, according to a global...


Magnetic anchoring device assisted-LSG is safe and effective
Magnetic anchoring device assisted-laparoscopic sleeve gastrectomy (MLSG) is safe and effective in terms of weight loss, shorter length...


Ultra-processed foods increase the risk of all-cause mortality and to 32 damaging health outcomes
Highly suggestive (class II) evidence indicates that higher exposure to ultra-processed foods is associated with an increased risk of 32...


Insulin-inhibitory receptor could be key to T2DM treatment
A novel study in mice with diet-induced obesity demonstrates that the knock-out of insulin-inhibitory receptor enhances glucose...


Journal Watch 28/2/2024
Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...


National Alliance of Healthcare Purchaser Coalitions releases employer recommendations to address obesity coverage
For over 30 years, the National Alliance of Healthcare Purchaser Coalitions (National Alliance) has united business healthcare coalitions...


Surgery more effective than medical and lifestyle interventions for diabetes control and remission
Bariatric surgery is more effective than medical and lifestyle modifications for achieving long-term type 2 diabetes control and...


Viking’s VK2735 demonstrates up to 14.7% mean body weight loss after 13 weeks
Patients receiving weekly doses of Viking Therapeutics’ VK2735, a dual agonist of the glucagon-like peptide 1 (GLP-1) and...
Browse by tag






bottom of page

